However, buparlisib showed low monotherapy efficacy in a phase II trial in patients with PI3K-activated glioblastoma (GBM), possibly due to insufficient inhibition of the PI3K pathway in the tumor.47 The gene discussed is PIK3CB; the disease is glioblastoma.